Literature DB >> 24679496

Pharmacologic management of portal hypertension.

Annalisa Berzigotti1, Jaime Bosch2.   

Abstract

Progress in the knowledge of the pathophysiology of portal hypertension has disclosed new targets for therapy, resulting in a larger spectrum of drugs with a potential role for clinical practice. This review focuses on pharmacologic treatments already available for reducing portal pressure and summarizes drugs currently under investigation in this field.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic liver disease; Drug therapy; Hepatic resistance; Portal pressure; Splanchnic blood flow

Mesh：

Substances：

Year:  2014        PMID： 24679496     DOI： 10.1016/j.cld.2013.12.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  11 in total

Review 1.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 2.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

Review 3.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

Authors:  Jaume Bosch; Roberto J Groszmann; Vijay H Shah
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 4.  Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension.

Authors:  Alberto Ferrarese; Alberto Zanetto; Giacomo Germani; Patrizia Burra; Marco Senzolo
Journal:  World J Hepatol       Date:  2016-08-28

Review 5.  Hypothalamic and inflammatory basis of hypertension.

Authors:  Sinan Khor; Dongsheng Cai
Journal:  Clin Sci (Lond)       Date:  2017-02-01       Impact factor: 6.124

Review 6.  Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Huijing Yao; Chunqing Zhang
Journal:  Ir J Med Sci       Date:  2018-02-22       Impact factor: 1.568

Review 7.  Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev; Evgeniy Leonidovich Kazachkov
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

8.  Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Steven Sourbron; Hersh Chandarana; Yohan Son; Susmita Basak; Kyoung-Bun Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Eur Radiol       Date:  2021-06-12       Impact factor: 5.315

9.  Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis.

Authors:  M Lunova; S Frankova; H Gottfriedova; R Senkerikova; M Neroldova; J Kovac; E Kieslichova; V Lanska; E Sticova; J Spicak; M Jirsa; J Sperl
Journal:  Physiol Res       Date:  2021-06-01       Impact factor: 1.881

10.  Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension.

Authors:  Umberto Vespasiani-Gentilucci; Krista Rombouts
Journal:  Gut       Date:  2014-06-25       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.